<DOC>
	<DOCNO>NCT01878812</DOCNO>
	<brief_summary>The purpose study ass , adult 18 year age , immunogenicity reactogenicity seasonal influenza vaccine , Fluarix/Influsplit Tetra contain four influenza strain ( two A strain two B strain ) 2013/2014 season .</brief_summary>
	<brief_title>Immunogenicity Safety Study GlaxoSmithKline ( GSK ) Biologicals ' Quadrivalent Influenza Vaccine , Fluarix/Influsplit Tetra® ( 2013/2014 Season ) , Adults 18 Years Age Older</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . A male female age 18 year time vaccination . Written inform consent obtain subject . Healthy subject subject wellcontrolled chronic disease establish medical history clinical examination enter study . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination . Participation previous year 's Fluarix registration study ( 116663 ) . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede dose study vaccine , plan use study period . Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug within six month prior vaccination . Inhaled topical steroid allow . Any administration longacting immunemodifying drug within 6 month study start , plan administration study period . Administration immunoglobulins and/or blood product within three month precede administration study vaccine plan administration study period . Administration influenza vaccine within twelve month precede study vaccination . Receipt vaccine study vaccine within 30 day study vaccination and/or plan receive vaccine study vaccine entire study period . Clinically virologically confirm influenza infection within six month precede study vaccination . Acute disease and/or fever time enrollment . Fever define temperature ≥ 37.5°C/99.5°F oral , axillary tympanic setting , ≥ 38.0°C/100.4°F rectal setting . The preferred route record temperature study axillary . Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever may enrol discretion investigator . Acute , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Chronic underlying disease ( cancer , chronic obstructive pulmonary disease oxygen therapy , insulindependent diabetes mellitus ) , stabilize clinically serious . History chronic alcohol consumption and/or drug abuse . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . History GuillainBarré syndrome . History allergic disease reaction likely exacerbate component vaccine include latex . Anaphylaxis follow administration vaccine ( ) . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution . Any condition , opinion investigator , prevents subject participate study would make intramuscular injection unsafe .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Influenza</keyword>
	<keyword>Adults</keyword>
	<keyword>Safety</keyword>
	<keyword>Elderly</keyword>
</DOC>